Related Experiment Video

Updated: Oct 30, 2025

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice
06:07

Oral Combinational Antiretroviral Treatment in HIV-1 Infected Humanized Mice

Published on: October 6, 2022

2.6K

Current treatment for hepatitis C virus/human immunodeficiency virus coinfection in adults

Ratchapong Laiwatthanapaisan1, Apichet Sirinawasatien2

  • 1Gastroenterology Center, Vibhavadi Hospital, Bangkok 10900, Thailand.

World Journal of Clinical Cases
|July 5, 2021
PubMed

Insights

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection accelerates liver disease. Direct-acting antiviral therapy is effective but presents unique challenges like drug interactions and reinfection risk in coinfected patients.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV)/human immunodeficiency virus (HIV) coinfection significantly increases morbidity and mortality in HIV-infected individuals.
  • HIV accelerates liver fibrosis progression, leading to cirrhosis and hepatocellular carcinoma in coinfected patients.
  • Management of coinfection is complicated by potential drug-drug interactions and high-risk behaviors leading to HCV reinfection.

Purpose of the Study:

  • To review the current management strategies for HIV/HCV coinfection.
  • To highlight the challenges and considerations in treating coinfected patients.

Main Methods:

  • Literature review of current research and clinical guidelines on HIV/HCV coinfection management.
  • Analysis of treatment efficacy and complications associated with direct-acting antiviral (DAA) therapy in coinfected individuals.

Main Results:

  • Direct-acting antiviral therapy demonstrates similar sustained virologic response rates for HCV in both coinfected and monoinfected patients.
  • Key challenges in managing HIV/HCV coinfection include managing drug-drug interactions between antiretrovirals and DAAs.
  • HCV reinfection is a significant concern due to ongoing high-risk behaviors in the coinfected population.

Conclusions:

  • Effective management of HIV/HCV coinfection requires careful consideration of drug interactions and strategies to prevent reinfection.
  • Optimizing treatment outcomes necessitates a comprehensive approach addressing both viral infections and patient behaviors.

Keywords:
Antiretroviral therapyCirrhosisDirect-acting antiviral agentsHepatocellular carcinomaHuman immunodeficiency virus, Liver fibrosisViral hepatitis C

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.1K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.8K

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
47.9K
Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
509
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.3K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
50
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
434
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
284